Issue of Shares

Wellnex Life Limited ("Wellnex" or the "Company") (ASX/AIM:WNX), an innovative consumer healthcare business with a track record for developing, licensing, and marketing products and brands to customers in the growing healthcare market segment, announces that it has issued 646,153 new ordinary shares of no par value each in the Company ("Ordinary Shares") at a reference price of A$0.65 per share, in settlement of fees in respect of an undertaking provided by Barclay Pearce Capital Investment Pty Limited to the Company at the time of its admission to AIM.

Further details in respect of the undertaking are set out in the Company's Admission Document.

Admission and Total Voting Rights

Application has been made to the London Stock Exchange for admission of the 646,153 Ordinary Shares to trading on AIM. It is expected that admission will become effective and dealings in the Ordinary Shares will commence on AIM at 8.00 a.m. on or around 22 May 2025.

Following Admission, the Company's issued share capital will comprise of 67,771,528 Ordinary Shares, none of which are held in treasury. Accordingly, the figure of 67,771,528 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules and the provisions of the Company's constitution.

This AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).